NGF
ENSG00000134259
Target class
Secreted protein
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
5
- Approved drugs
- 0
- ClinGen gene-disease validity
- Strong
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- NGF
- Gene name
- Nerve growth factor
- Gene symbol
- NGF
- Previous gene symbols
- NGFB
- Protein name
- Beta-nerve growth factor (Beta-NGF)
- Gene biotype
- Protein coding
- Gene family
- Neurotrophins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 43
- Highest tissue expression
- 33.47
- Tissue specificity (Gini)
- 0.605
- Tissue specificity (tau)
- 0.817
- KEGG gene identifiers
- hsa:4803
- Protein interaction confidence
- 0.795136
- Protein interaction partners
- 88
- R-HSA-167021
- R-HSA-167044
- R-HSA-167060
- R-HSA-170968
- R-HSA-170984
- R-HSA-177504
- R-HSA-187042
- R-HSA-187706
- R-HSA-193648
- R-HSA-193670
- R-HSA-193681
- R-HSA-198203
- R-HSA-198745
- R-HSA-205017
- R-HSA-205025
- R-HSA-205043
- R-HSA-209543
- R-HSA-209560
- R-HSA-209563
- End position
- 115338770
- Start position
- 115285904
- Chromosome
- 1
- Strand
- Reverse
- Secreted . Endosome lumen . Note=ProNGF is endocytosed after binding to the cell surface receptor formed by SORT1 and NGFR. .
Publication evidence
- PubMed 20978020
- Tissue specificity (tau)
- 0.816716
- Expression inequality (Gini)
- 0.605199
Expression in transcripts per million
- Ovary
- 33.47
- Artery - Aorta
- 29.99
- Fallopian Tube
- 28.12
- Uterus
- 22.64
- Artery - Tibial
- 21.92
Expression in transcripts per million
- Ovary33.47
- Artery - Aorta29.99
- Fallopian Tube28.12
- Uterus22.64
- Artery - Tibial21.92
- Adipose - Visceral (Omentum)19.42
- Artery - Coronary17.7
- Nerve - Tibial16.53
- Cervix - Endocervix16.47
- Heart - Atrial Appendage16.32
- Cervix - Ectocervix12.99
- Kidney - Medulla8.28
- Bladder7.6
- Vagina7.52
- Heart - Left Ventricle7.21
- Colon - Sigmoid7.14
- Cells - Cultured fibroblasts6.98
- Adipose - Subcutaneous6.61
- Thyroid6.16
- Breast - Mammary Tissue5.62
- Spleen5.54
- Esophagus - Gastroesophageal Junction5.08
- Esophagus - Muscularis4.43
- Prostate3.94
- Kidney - Cortex3.76
And 29 more, listed on the interactive page.
- GO:0008285
- GO:0008625
- GO:0010628
- GO:0045666
- GO:0048812
- GO:0005576
- GO:0005796
- GO:0005829
- GO:0005515
- GO:0008191
Related records
Trials (78)
- A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
- A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
- A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
- A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
- A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
- A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
- A Phase 3 Study of Tanezumab for Chronic Low Back Pain
- A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
- A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
- A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
- A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
- A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
- A Study of Tanezumab in Adults With Chronic Low Back Pain
- A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
- A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
- A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
Drugs (5)
- Fasinumab Beta-nerve growth factor inhibitor
- Fulranumab Beta-nerve growth factor inhibitor
- MEDI-578 Beta-nerve growth factor inhibitor
- PG-110 Beta-nerve growth factor inhibitor
- Tanezumab Beta-nerve growth factor inhibitor